After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Tarsus Pharmaceuticals Inc is $2.89B. A total of 0.67 million shares were traded on the day, compared to an average of 679.71K shares.
In the most recent transaction, Azamian Bobak R. sold 6,000 shares of TARS for 55.37 per share on Sep 24 ’25. After the transaction, the President/CEO and Board Chair now owns 812,106 company shares. In a previous transaction on Sep 24 ’25, Bobak Azamian Living Trust bought 6,000 shares at 55.37 per share.
Among the insiders who sold shares, LINK WILLIAM J PHD disposed of 27,116 shares on Sep 08 ’25 at a per-share price of $57.00. This resulted in the Director holding 143,332 shares of TARS after the transaction. In another insider transaction, LINK WILLIAM J PHD bought 27,116 shares at $57.01 per share on Sep 08 ’25.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, TARS has a high of $68.00 and a low of $32.91.
As of this writing, TARS has an earnings estimate of -$0.35 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.32 per share and a lower estimate of -$0.38. The company reported an EPS of -$0.61 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. TARS’s latest balance sheet shows that the firm has $171.81M in Cash & Short Term Investments as of fiscal 2021. There were $1.89M in debt and $11.48M in liabilities at the time. Its Book Value Per Share was $7.88, while its Total Shareholder’s Equity was $166.73M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TARS is Buy with a score of 4.56.
